News
PGEN
1.680
+1.20%
0.020
Precigen Insiders Placed Bullish Bets Worth US$1.72m
In the last 12 months Precigen, Inc. Insiders bought US$998k worth of shares at a price of US$1.75 per share. In the last year there was more buying than selling of shares in Precigen. The company owns about US$15m of shares. Our analysis of the insider transactions at Precigen shows the company has grown in value over the past year. An insider's optimism about the company's prospects is a positive sign. Precigen is not the only stock insiders are buying.
Simply Wall St · 2d ago
Precigen To Spearhead First Potential Gene Therapy Launch
Phil Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of PRGN-2012 in recurrent respiratory papillomatosis. Company strengthens focus on building and optimizing commercial readiness and pre-launch activities.
Benzinga · 3d ago
Press Release: Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
Dow Jones · 3d ago
Weekly Report: what happened at PGEN last week (0715-0719)?
Weekly Report · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Allstate, Quanta, First Industrial Realty
Wall Street's major indexes reversed early gains on Thursday. The Dow Jones Industrial Average was down 0.66% at 40,925.7. The top three S&P 500 percentage gainers were D.R. Horton, Barnes & Noble and First Industrial Realty.
Reuters · 07/18 17:56
BUZZ-U.S. STOCKS ON THE MOVE-Meta Platforms, Cintas, Toast
The Nasdaq and the S&P 500 bounced back on Thursday. An upbeat forecast from Taiwan Semiconductor Manufacturing lifted chip stocks after a sharp sell-off in the previous session. The Dow Jones Industrial Average was down 0.80% and the Nasdaq Composite was also down. Meta Platforms, Cintas and Toast are up.
Reuters · 07/18 16:49
Weekly Report: what happened at PGEN last week (0708-0712)?
Weekly Report · 07/15 09:22
Weekly Report: what happened at PGEN last week (0701-0705)?
Weekly Report · 07/08 09:23
Precigen’s Annual Meeting Decisions and Director Departure
TipRanks · 07/05 21:48
Precigen, Inc.'s (NASDAQ:PGEN) market cap dropped US$45m last week; individual investors who hold 36% were hit as were institutions
Private equity firms own 36% of Precigen, Inc. (NASDAQ:PGEN) The company has a total of 51% of the company. 3 of the top 5 shareholders have a majority stake in Precigen. The company is not owned by hedge funds. Precigen has a market cap of just US$391m. It is owned by 3 investors with a 51% stake in the company, with 30% of shares held by institutional investors. The majority of shares are held by private equity firms, with the rest of the shares owned by the general public. It's worth looking at the company's ownership of shares to see who really controls Precigen and its future.
Simply Wall St · 07/03 11:21
Weekly Report: what happened at PGEN last week (0624-0628)?
Weekly Report · 07/01 09:23
Weekly Report: what happened at PGEN last week (0617-0621)?
Weekly Report · 06/24 09:24
Weekly Report: what happened at PGEN last week (0610-0614)?
Weekly Report · 06/17 09:22
Weekly Report: what happened at PGEN last week (0603-0607)?
Weekly Report · 06/10 09:23
Precigen Price Target Maintained With a $14.00/Share by JMP Securities
Dow Jones · 06/04 12:42
JMP Securities Reiterates Market Outperform on Precigen, Maintains $14 Price Target
Benzinga · 06/04 12:32
Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
Precigen, Inc. Shareholders are up 15% in the last week. The share price of the company has dropped 78% over the last three years. The company saw its revenue shrink by 61% per year in the same period. Precigen's share price is up 16% for the year, but the company is not profitable.
Simply Wall St · 06/04 11:08
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
SAIC shares dipped 11% to $119.91 following first-quarter results. GameStop Corp. Shares climbed 34.5% after Roaring Kitty on a Reddit post, shared his position on the stock. Microbot Medical Inc. Shares jumped 92.5%; Bio-Path Holdings, Inc. Jumped 75%.
Benzinga · 06/03 17:56
6 Analysts Assess Precigen: What You Need To Know
Precigen (NASDAQ:PGEN) is a biotechnology company that develops synthetic biology solutions. The company has an average 12-month price target of $8.17. In the last quarter, 6 analysts have upgraded their ratings of the company to 'buy' from 'hold' The company's revenue growth rate is lower than its industry peers.
Benzinga · 06/03 17:00
Precigen Is Maintained at Buy by Stifel
Dow Jones · 06/03 16:30
More
Webull provides a variety of real-time PGEN stock news. You can receive the latest news about Precigen Inc through multiple platforms. This information may help you make smarter investment decisions.
About PGEN
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.